Chikungunya Vaccine, Recombinant (Bavarian Nordic)(Chikungunya Vaccine, Recombinant (Bavarian Nordic))

概要

基本信息

药物类型

病毒样颗粒疫苗、治疗性疫苗

别名

Alum-adjuvanted chikungunya virus-like particle vaccine、Chikungunya virus virus-like particle vaccine、Chikungunya-virus-vaccine-VRC

+ [6]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染其他疾病

在研适应症

基孔肯雅热

非在研适应症-

原研机构

PaxVax Holding Co., Ltd.

在研机构

Bavarian Nordic A/S

非在研机构

Emergent BioSolutions, Inc.National Institute of Allergy & Infectious Diseases

权益机构

Emergent BioSolutions, Inc.

Bavarian Nordic A/S

Emergent Travel Health, Inc.

+ [3]

最高研发阶段批准上市

首次获批日期

美国 (2025-02-14),

基孔肯雅热

最高研发阶段(中国)-

特殊审评优先审评 (美国)、突破性疗法 (美国)、加速审评 (欧盟)、优先药物（PRIME） (欧盟)、快速通道 (美国)

登录后查看时间轴

结构/序列

Sequence Code 9535613

Sequence Code 10051604

Sequence Code 10051610

关联

11

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的临床试验

NCT07467707

/ Not yet recruiting临床3期

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to <18 Years) and Adults (≥18 Years)

Study EBSI-CV-317-007 is a field study to evaluate the efficacy, immunogenicity, and safety of CHIKV VLP vaccine. The study was designed using infectious disease models and advanced analytics to guide region and clinical site prioritization, define the timing of study activities, and optimize the study parameters to local epidemiological conditions for CHIKV disease to overcome the challenges of assessing efficacy for CHIKV VLP vaccine.

开始日期2026-05-01

申办/合作机构

Bavarian Nordic A/S

[+2]

NCT07003984

/ Recruiting临床3期

A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled, Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children 2 to <12 Years of Age

The goal of this multi-center, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity of CHIKV VLP Vaccine in children 2 to <12 years of age.

开始日期2025-06-05

申办/合作机构

Bavarian Nordic A/S

NCT06007183

/ Active, not recruiting临床3期

A Long-term Follow-up Study to Evaluate Safety and Immunogenicity of a Chikungunya Virus Virus-like Particle Vaccine (PXVX0317) in Healthy Adults and Adolescents After Either a Single or Booster Vaccination Dosing Regimen

The purpose of this phase 3 multicenter, randomized, double-blind, placebo-controlled rollover study is to evaluate the safety and long-term immunogenicity of CHIKV VLP vaccine in adult and adolescent participants and to evaluate CHIKV VLP booster vaccine induced serum neutralizing antibody (SNA) response at 3, 4, or 5 years post-initial CHIKV VLP vaccination.

开始日期2023-08-30

申办/合作机构

Bavarian Nordic A/S

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的临床结果

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的转化医学

登录后查看更多信息

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的专利（医药）

登录后查看更多信息

108

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的文献（医药）

2026-03-01·VACCINE

Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya

Review

作者: Schönfeld, Christian ; Grünewald, Thomas ; Branke, Lisa ; Kling, Kerstin ; Ramharter, Michael ; Falman, Annika ; Rothe, Camilla

BACKGROUND:

Infections with the chikungunya virus are increasingly reported due to many reasons including climate change. Two vaccines against chikungunya have recently been approved in Europe, the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. However, no systematic review of phase 3 clinical trial data has been published that summarizes the currently available evidence on the immunogenicity, tolerability, and safety of these vaccines. Therefore, these data were systematically analyzed by a working group of the German Standing Committee on Vaccination (STIKO) and the German Society for Tropical Medicine, Travel Medicine and Global Health (DTG).

METHODS:

We conducted a systematic review of the immunogenicity, tolerability and safety of Ixchiq and Vimkunya using Embase and PubMed (OVID) according to predefined PICO criteria, including placebo-controlled randomized control trials, cohort, and case-control studies. Risk of bias (RoB) was assessed with the RoB 2-tool. Additionally, post-marketing safety data were studied.

RESULTS:

Clinical efficacy data were not available. Instead, seropositivity rates above a predefined threshold served as a surrogate of protection. Both vaccines demonstrated strong immunogenicity with seroprotection rates for Ixchiq of >98% after 4 weeks, and for Vimkunya after 3 weeks of >97% in 12-59-year-olds and > 87% in ≥65-year-olds. In the pivotal studies, both vaccines showed also an acceptable safety profile. Post-marketing safety data showed a higher risk for serious adverse events in elderly patients for Ixchiq.

CONCLUSION:

In addition to mosquito protection and vector control, two vaccines with a good efficacy profile based on the surrogate marker of seroprotection are now available to prevent chikungunya. While both vaccines showed acceptable tolerability, the safety of vaccines must be continuously assessed based on further data from post-marketing surveillance of the respective populations.

2026-02-01·Current Opinion in Virology

A storm is born: immune activation and pathogenesis in arthritogenic alphavirus infections

Review

作者: Koo, Yong Qian ; Freppel, Wesley ; Herrero, Lara J

Arthritogenic alphaviruses, including chikungunya (CHIKV), Ross River, and Mayaro viruses, are emerging global viruses responsible for causing arthralgia and chronic arthritis. Following mosquito-borne transmission, they quickly initiate infection in the skin, including in resident immune cells, and disseminate systemically into musculoskeletal tissues. The innate immune system responds rapidly through the activation of interferons, the production of inflammatory cytokines, and the recruitment of monocytes, macrophages, neutrophils, and dendritic cells, while the adaptive immune response, particularly virus-specific T and B cells, is critical for viral clearance. However, excessive immune activation can lead to both acute and chronic musculoskeletal pain through cytokine storm, tissue damage, and supporting immunopathology. Additionally, viral persistence and immune evasion may contribute to the development of chronic synovitis and cartilage degradation, leading to persistent joint pain. Despite recent advances, antiviral treatments remain unavailable, and to date, there is only one vaccine licensed (VIMKUNYA™ in 2025, against CHIKV), underscoring the urgent need for further research. This review explores the complex interplay between host immune responses and viral factors that lead from acute infection to chronic inflammation. Furthermore, it highlights key gaps in understanding viral persistence and immune evasion, and how to predict chronic diseases to improve therapeutic and preventive strategies against arthritogenic alphaviruses.

2025-12-31·Expert Review of Vaccines

Virus-like particles: a versatile and effective vaccine platform

Review

作者: Bachmann, Martin F. ; Lienert, Florian ; Schwarz, Tino F. ; van Damme, Pierre

INTRODUCTION:

Traditional live-attenuated or inactivated vaccines have limitations, including risks associated with uncontrolled replication, reduced immunogenicity, or production complexities. To address these issues, alternative platforms such as virus-like particles (VLPs) have been developed.

AREAS COVERED:

VLPs are self-assembling structures composed of viral proteins that mimic native viruses but are noninfectious. This review provides an overview of their structure, design and manufacture that make them an attractive platform for vaccine development. We then discuss the clinical development of some recently approved VLP vaccines and those widely used in immunization programs, summarizing the clinical trial data that underpins their efficacy and safety profiles. Additionally, we explore VLP vaccines in late-stage clinical development for respiratory syncytial virus and human metapneumovirus.

EXPERT OPINION:

VLPs are a versatile and promising platform for vaccine development. Their ability to mimic native viruses while eliminating the risks associated with live vaccines positions them as an attractive platform for vaccine design. Currently approved VLP vaccines demonstrate that they can provide effective protection against a wide range of diseases. Advances in VLP design and production are likely to lead to highly effective vaccines, significantly contributing to global immunization efforts.

100

项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的新闻（医药）

2026-03-12

·Pharmaceutical Technology

Bavarian Nordic and SII sign agreement for chikungunya vaccine production

The vaccine is a single-dose, prefilled product for immunisation against the chikungunya virus in individuals aged 12 and above. Credit: Kitsawet Saethao / Shutterstock.com. Bavarian Nordic has signed a manufacturing agreement with Serum Institute of India (SII), expanding its strategic partnership through a contract for its chikungunya vaccine (CHIKV VLP). The contract covers a full technology transfer for the vaccine manufacturing process from Bavarian Nordic to SII, aiming to increase production capacity and future supply for endemic low- and middle-income countries. The new arrangement builds upon the existing licence and manufacturing partnership between the two companies for the mpox vaccine. It replaces an earlier deal with Biological E. Both parties will also explore potential co-development opportunities as part of this extended collaboration. Bavarian Nordic’s president and CEO Paul Chaplin said: “We are pleased to strengthen our strategic partnership with Serum Institute of India. “By leveraging the strengths of both organisations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe.” GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence The CHIKV VLP vaccine is a prefilled, single-dose, adjuvanted virus-like particle recombinant protein product intended for active immunisation against disease caused by the chikungunya virus in people aged 12 years and above. It is designed to trigger a strong seroresponse, with protective immunity beginning to develop as soon as one week following vaccination. As it does not contain viral genetic material, the vaccine is non-infectious and cannot cause disease, making it suitable for a broad population demographic. Marketed as Vimkunya, CHIKV VLP has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), the European Commission, and the US Food and Drug Administration (FDA) in 2025. Regulatory review is underway in Canada and Switzerland. In September 2025, Bavarian Nordic launched its chikungunya vaccine, Vimkunya, in the UK. The launch followed a significant increase in travel-related disease cases reported nationwide. The UK Health Security Agency (UKHSA) stated that incidences rose by 170% in August 2025 compared with the same period in 2024.

疫苗上市批准引进/卖出

2026-03-11

·BioSpace

Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

The agreement enables a full tech transfer of the chikungunya vaccine for future supply to low- and middle-income countries. Expanded collaboration provides future co-development opportunities. COPENHAGEN, Denmark, March 11, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced an expansion of the strategic partnership with Serum Institute of India Pvt. Ltd. (SII) to include a contract manufacturing agreement covering a full tech transfer of the manufacturing process for the chikungunya vaccine (CHIKV VLP) from Bavarian Nordic to SII to allow for scaling of capacity to enable future supply to endemic low- and middle-income countries (LMICs). This agreement builds on the existing mpox vaccine license and manufacturing agreement with SII, and replaces the agreement previously entered with Biological E. Limited. In addition, through this expanded collaboration, the parties will explore potential future co-development opportunities. “ We are pleased to strengthen our strategic partnership with Serum Institute of India. B y leveraging the strengths of both organizations, we can scale manufacturing of our chikungunya vaccine to expand global supply and improve access for populations around the globe,” said Paul Chaplin, President & CEO of Bavarian Nordic . About CHIKV VLP CHIKV VLP is a single dose, prefilled, adjuvanted VLP recombinant protein vaccine for active immunization for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. It is designed to induce a robust seroresponse, with protective immunity starting to develop as early as 1 week after vaccination. The vaccine does not contain viral genetic material and is therefore non-infectious and unable to cause disease, ensuring a broad range of people can benefit from vaccination. CHIKV VLP (marketed as Vimkunya ® ) has been approved by the U.S. Food and Drug Administration, the European Commission and the U.K. Medicines & Healthcare products Regulatory Agency in 2025. Regulatory review of the vaccine is ongoing in Switzerland and Canada. About chikungunya Chikungunya is a mosquito-borne disease caused by the chikungunya virus. In the past 20 years, the virus has emerged across several regions in Asia, Africa, and the Americas, including many popular travel destinations, often causing large unpredictable outbreaks. Since its discovery, chikungunya has been identified in more than 110 countries 1 . Chikungunya typically presents with acute symptoms, including fever, rash, fatigue, headache, and often severe and incapacitating joint pain. Most patients recover, but 30-40% of those affected may develop chronic symptoms that can last for months or even years 2 . In 2025, as of December, nearly 500,000 cases of chikungunya and over 200 associated deaths were reported worldwide 3 . More than half of the reported cases and associated deaths were reported from Brazil 4 . Recent data suggest that chikungunya is severely underreported and often misdiagnosed as dengue fever due to a similar symptom profile 5 . About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit . About Serum Institute of India Serum Institute of India Pvt. Ltd. is the world’s largest vaccine manufacturer, developing life-saving vaccines against diseases including polio, measles, meningitis, rotavirus, diphtheria, tetanus, malaria, HPV, pneumonia, and COVID-19, with a mission to make affordable vaccines accessible worldwide. Present across 170+ countries, including the U.S., the UK, and Europe, SII operates one of the largest multifunctional vaccine production facilities in Manjri, Pune, with an annual capacity of 4 billion doses, contributing to saving over 30 million lives over the years. For more information, visit . Contact investors: Europe: Disa Tuominen, IR Manager, detu@bavarian-nordic.com US: Graham Morrell, Gilmartin Group, graham@gilmartinir.com , Tel: +1 781 686 9600 Contact media: Nicole Seroff, Vice President Corporate Communications, nise@bavarian-nordic.com , Tel: +45 53 88 06 03 1 World Health Organization (WHO). Chikungunya. 2 European Centre for Disease Prevention and Control. Chikungunya virus disease . . 3 European Centre for Disease Prevention and Control. Chikungunya virus disease worldwide overview . . 4 Pan American Health Organization (PAHO). Chikungunya: analysis by country. 5 Ribas Freitas AR, Pinheiro Chagas AA, Siqueira AM, Pamplona de Góes Cavalcanti L. How much of the current serious arbovirus epidemic in Brazil is dengue and how much is chikungunya? Lancet Reg Health Am. 2024 Apr 30;34:100753. doi: 10.1016/j.lana.2024.100753. PMID: 38711542; PMCID: PMC11070701. Attachment Bavarian Nordic and Serum Institute of India Expand Strategic Partnership with Chikungunya Vaccine Manufacturing Agreement

上市批准疫苗引进/卖出

2026-03-03

·药时空

丹疫苗巨头 CEO 离任，收购失利成转折

摘要：丹麦疫苗企业巴伐利亚北欧 CEO 保罗・查普林宣布卸任，其执掌公司 12 年，带领企业从研发小厂成长为跨国疫苗商，猴痘疫苗 Jynneos、基孔肯雅热疫苗 Vimkunya 均是其任期内的重要成果。此次离任距公司私募收购失败仅数月，董事会已启动新任 CEO 搜寻，查普林将留任至 2026 年或继任者到任。掌舵十二载，一朝官宣离场 3 月 2 日的一纸公告，让保罗・查普林的名字和巴伐利亚北欧的管理层变动绑在一起。这位 1999 年就加入公司、2014 年接棒 CEO 的老将，要走了。他在声明里提了离任的原因，家人想回澳大利亚。其实明眼人都能看出来，这时间点多少有点微妙。去年 11 月，公司董事会主席刚因私募收购失败下台，时隔四个月，CEO 也官宣离场，这家丹麦疫苗公司的管理层，算是经历了一波不小的震荡。公司说，和查普林签了协议，他会继续干到 2026 年，或者等新 CEO 选出来为止。至于新老板从哪找，内部提拔还是外部挖角，董事会没细说，只说已经开始找了。任期里的那些亮眼答卷坦白讲，查普林这十二年，把巴伐利亚北欧的底子铺得很实。接手时还是个偏居丹麦的研发小公司，走的时候，已经是能在全球多个市场跑业务的疫苗大厂了。最出圈的当属 Jynneos 疫苗。2022 年猴痘全球暴发，这款原本针对天花的疫苗，成了欧美各国的防疫利器，不管是美国还是其他国家，都靠它撑起了猴痘预防的半边天。这波操作，让巴伐利亚北欧一下子走到了全球防疫的台前。还有 2023 年那笔收购，拿下了 Emergent Biosolutions 的旅行疫苗业务，后续还把基孔肯雅热疫苗 Vimkunya 推上了 FDA 批准的舞台。虽说这款疫苗比竞品晚了一步上市，但竞品今年 1 月因为严重不良反应被 FDA 调查，直接撤了美国市场，倒让 Vimkunya 占了先机。查普林自己也说，近三十年的经历很珍贵，带着团队做拯救生命的事，也算交出了不错的答卷。收购黄了，成了绕不开的坎查普林其实对公司的未来有过别的设想。他曾寄希望于私募收购，想着靠这笔钱给公司加把劲，把那些被认为 “不受重视” 的产品盘活，变成新的增长点。去年 8 月他就和彭博社聊过，牵头的北欧资本和 Permira 都愿意砸钱，也清楚公司需要持续的资金投入。但这事最终还是黄了，去年 11 月，因为股东支持率不够，这场收购直接泡汤。收购失利的连锁反应来得很快，前董事会主席吕克・德布鲁因当即宣布下台，说要让董事会专心搞公司下一阶段的发展。如今查普林也离场，这场收购失败，成了这家公司近期绕不开的一个坎。其实回头看，查普林的离开，对巴伐利亚北欧来说，算是一个阶段的结束。他打下的疫苗基础还在，只是接下来，新的掌舵人要怎么接棒，怎么避开之前的坑，把这些疫苗产品的价值再挖深挖透，都是实打实的考验。参考来源：https://www.fiercepharma.com/pharma/bavarian-nordics-longtime-ceo-telegraphs-exit-joining-board-chair-who-departed-after-failed 识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

疫苗并购高管变更信使RNA

100 项与 Chikungunya Vaccine, Recombinant (Bavarian Nordic) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
基孔肯雅热	美国	Bavarian Nordic A/S	2025-02-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ACR2025	临床2/3期	基孔肯雅热	3,141	CHIKV VLP vaccine	艱餘遞顧鑰鑰壓壓鹽積(艱糧糧築壓鏇繭製艱艱) = 鹹衊鹽製選衊範觸選鏇壓簾願廠蓋願鹹獵鬱網 (範膚遞齋網衊繭壓壓糧 ) 更多	积极	2025-10-24
				Placebo	選衊遞製膚醖憲鏇構築(夢淵遞觸衊鑰願製襯襯) = 壓遞廠膚廠憲簾構獵鏇願簾衊齋築糧構淵網襯 (艱襯製餘鹽鏇構夢積範 )
NCT03992872 (Pubmed \| Lancet Microbe)	临床2期	甲病毒感染	60	Previous alphavirus vaccine recipients	夢製餘鬱願繭積製淵糧(築構壓壓鹹選糧齋網衊) = There was no statistically significant difference in the incidence of solicited adverse events between the previous alphavirus vaccine recipients and alphavirus vaccine-naive controls (53.3% vs 40.0%, respectively), although the relatively small sample size of the trial limited the power to detect a significant difference, and there were no reported vaccine-related serious adverse events 艱繭繭醖製願選構築壓 (夢淵鹽衊顧鑰鬱觸製襯 )	积极	2025-04-01
				Alphavirus vaccine-naive controls
NCT05072080 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	窪範襯繭餘壓糧艱構憲(齋淵築製膚積糧積顧夢) = 網餘觸襯獵鏇壓糧範積觸網膚襯壓衊網糧憲蓋 (餘醖夢築糧膚鏇願鹽壓, 1504.1 ~ 1695.6) 更多	积极	2025-02-14
				Placebo	窪範襯繭餘壓糧艱構憲(齋淵築製膚積糧積顧夢) = 網衊糧壓積壓齋製艱齋觸網膚襯壓衊網糧憲蓋 (餘醖夢築糧膚鏇願鹽壓, 7.0 ~ 8.8) 更多
NCT05349617 (FDA_CBER) 人工标引	临床3期	基孔肯雅热	-	VIMKUNYA	鬱簾築選艱鹽襯鹽築構(衊醖範襯積鏇蓋鬱鏇鹽) = 艱顧願製鏇網繭壓衊夢膚構鏇鹽衊鹽繭糧觸積 (衊願醖鑰襯窪範網壓顧, 582.3 ~ 892.7) 更多	积极	2025-02-14
				Placebo	鬱簾築選艱鹽襯鹽築構(衊醖範襯積鏇蓋鬱鏇鹽) = 膚鏇壓廠積淵觸憲醖衊膚構鏇鹽衊鹽繭糧觸積 (衊願醖鑰襯窪範網壓顧, 6.5 ~ 10.0) 更多
NCT05349617 (CTgov)	临床3期	-	413	CHIKV VLP/adjuvant (Group 1 - PXVX0317)	製壓構鹽觸窪觸鏇積鹽 = 壓膚襯蓋遞繭繭範積壓膚範醖獵鏇繭廠夢選壓 (獵憲繭夢鹽顧鏇觸構艱, 顧壓範鑰齋憲蓋鹽願襯 ~ 齋顧繭淵壓餘簾淵鏇憲) 更多	-	2024-12-13
				Placebo (Group 2 - Placebo)	製壓構鹽觸窪觸鏇積鹽 = 艱簾衊網鹽簾衊襯鏇鑰膚範醖獵鏇繭廠夢選壓 (獵憲繭夢鹽顧鏇觸構艱, 醖襯膚憲醖窪範網築窪 ~ 鑰淵鬱醖衊簾構簾願顧) 更多
NCT05072080 (CTgov)	临床3期	基孔肯雅热	3,258	CHIKV VLP/adjuvant (Group 1)	鬱夢衊廠鑰壓鑰遞襯蓋 = 構繭簾遞鹹醖觸襯顧簾觸積鏇艱觸襯網築齋醖 (構艱鬱選鹽範夢網夢選, 網蓋艱醖鹹鹽淵繭願遞 ~ 淵蓋衊夢鹽遞簾憲鹽獵) 更多	-	2024-08-30
				CHIKV VLP/adjuvant (Group 2)	鬱夢衊廠鑰壓鑰遞襯蓋 = 範選鹹鑰襯築衊襯廠糧觸積鏇艱觸襯網築齋醖 (構艱鬱選鹽範夢網夢選, 餘艱構蓋壓遞壓獵蓋顧 ~ 遞鬱獵窪餘願鬱鹹觸醖) 更多
NCT02562482 (phase 2, Pubmed \| Vaccine)	临床2期	基孔肯雅热 focus reduction neutralizing antibody	400	CHIKV VLP vaccine seropositive recipients	淵積顧糧衊窪膚觸襯衊(窪夢淵齋餘襯鏇淵簾蓋) = 蓋鬱齋鹹蓋餘網齋築襯鹽廠夢積鏇觸範餘範築 (餘遞構願選獵醖鏇願齋 )	积极	2023-10-01
				CHIKV VLP vaccine seronegative recipients	淵積顧糧衊窪膚觸襯衊(窪夢淵齋餘襯鏇淵簾蓋) = 鏇鏇艱範襯齋鑰醖鏇淵鹽廠夢積鏇觸範餘範築 (餘遞構願選獵醖鏇願齋 )
NCT05065983 (CHIKV VLP, CTgov)	临床2期	基孔肯雅热	25	CHIKV VLP, adjuvanted	願觸齋憲築網膚獵蓋襯 = 夢夢醖蓋餘淵糧襯鬱選鬱齋鹹窪網廠網艱醖鹹 (蓋鏇積獵簾構壓鏇膚窪, 鹹艱餘憲窪廠壓願膚糧 ~ 鑰廠製觸簾顧築鏇鏇願) 更多	-	2023-02-28
NCT03992872 (WRAIR, Biospace) 人工标引	临床2期	甲病毒感染 \| 基孔肯雅热	60	PXVX 0317	範築積簾鹽襯築選鑰網(製簾蓋餘鹹鏇製鹽淵獵) = The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. 鑰夢廠繭衊鏇獵廠淵繭 (鹹觸觸糧淵積願遞淵襯 )	积极	2022-11-01
NCT02562482 (Pubmed \| J Coll Physicians Surg Pak) 人工标引	临床2期	基孔肯雅热	400	PXVX-0317	鑰鬱遞鏇鑰餘廠廠繭獵(鹹艱鏇壓淵構積襯餘襯) = 簾簾餘網鹹積積淵鑰遞積願築繭襯繭膚衊範窪 (夢繭艱遞積構獵憲築膚 ) 更多	积极	2020-04-14
				Placebo	鑰鬱遞鏇鑰餘廠廠繭獵(鹹艱鏇壓淵構積襯餘襯) = 獵構網醖醖網鏇夢願鑰積願築繭襯繭膚衊範窪 (夢繭艱遞積構獵憲築膚 ) 更多